GLP-1 weight loss journeys on TikTok: what the data actually says

What did @reallyemely actually say?

She said tirzepatide (Mounjaro) worked for her, but not the way most people expect. After semaglutide ("the big O") failed her, she switched to tirzepatide and used it for two to three months. Her core claim: "All it did was help with my binge eating." She explicitly says appetite suppression did not kick in for her the way it does for others, and that her weight loss came from consistent cardio and hard work, not from the medication killing her hunger. She also disclosed insulin resistance and PCOS as complicating factors.

This is a more nuanced story than most GLP-1 content on TikTok. She is not claiming the drug is a miracle. She is claiming it had a partial, specific effect on her eating behavior, and that everything else required effort. That deserves an honest look.

Does the science back this up?

Partially, yes. The idea that GLP-1 and GIP receptor agonists reduce binge eating is supported by real data, and the claim that responses vary significantly between patients is not controversial at all.

Tirzepatide's primary mechanism includes slowing gastric emptying and acting on appetite-regulating centers in the brain, which typically reduces overall caloric intake. But the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed a wide distribution in weight loss outcomes, ranging from minimal response to over 20% body weight reduction. Not everyone gets uniform appetite suppression.

On binge eating specifically: a 2023 review by Kornstein et al. in the Journal of Clinical Psychiatry found that GLP-1 receptor agonists showed promising signals for reducing binge eating episodes, likely through dopaminergic reward pathway modulation, not just appetite suppression. So her observation that it helped with binge eating without fully suppressing appetite is biologically plausible. PCOS and insulin resistance can also affect how the body responds to these agents, as insulin signaling interacts with GLP-1 receptor sensitivity.

What did they get wrong (or right)?

She got the binge eating mechanism directionally right, but her explanation of why people lose weight on these drugs is oversimplified. She says the reason people lose weight is because it "completely suppresses their appetite." That is not the full picture.

Appetite suppression is one pathway, but tirzepatide also works by improving insulin sensitivity, reducing fat storage signals, and altering energy expenditure at a cellular level. The dual GIP and GLP-1 agonism in tirzepatide is distinct from semaglutide's single-pathway approach, which may explain differential responses. Framing it as purely appetite suppression flattens a more complex pharmacology.

That said, her personal account of a blunted appetite response is not implausible. A subset of patients in clinical trials report reduced efficacy, particularly those with higher baseline insulin resistance. Her self-awareness about this and her refusal to claim the drug did more than it did is actually more honest than a lot of weight loss content online. Credit where it is due.

What should you actually know?

GLP-1 and GIP receptor agonists are not uniform tools. Response varies by individual metabolic profile, comorbidities, dose titration, and duration of use. PCOS, which affects insulin sensitivity and hormonal regulation, is associated with variable GLP-1 receptor responsiveness according to research by Jensterle et al. (2022, Frontiers in Endocrinology).

If you have PCOS or insulin resistance and are considering these medications, the clinical conversation matters more than any TikTok outcome. Some patients do experience primarily behavioral changes, like reduced binge urges, without dramatic appetite suppression. That does not mean the drug failed. It may mean it worked differently.

Binge eating disorder and subclinical binge eating are also underdiagnosed and undertreated. The fact that she describes this as a longstanding struggle, and that the medication helped specifically there, is consistent with emerging research on these drugs as potential adjuncts for eating behavior, not just weight loss.

• Tirzepatide is FDA-approved for weight management under the brand name Zepbound and for type 2 diabetes as Mounjaro. These are not interchangeable labels.
• No medication replaces behavioral and lifestyle changes for long-term weight management.
• If a GLP-1 agent does not seem to be working for you, that is a conversation to have with a prescriber, not a reason to self-adjust dosing.